ABSTRACT
Candida albicans is the most common deep infection fungus, heads the list in clinic pathogenic fungi, can cause infections of the skin, mucosa, lungs, bronchial, intestinal tract and also is the very common pathogen in AIDS, tuberculosis and tumor patient (Chen. S.Y. et al. 2008; HernándezHernández. F. et al. 2003; Wu. S.W. et al. 2009; Zhao. D.J. et al. 2009). The isolated rate is 80.8% which is the most high from trichomoniasis and the infection rate is 43% in respiration medicine which is the most high compared with department (Zhao. D.J. et al. 2009; Zhan. Y. et al. 2010). The medications curing fungus deep infection most are deleterious, so there are limitations in clinical application. While the bulk antifungal agent have been applied in clinic, the fungus resistance to these agents appeared and is tend to be serious, for example, the azole drug resistance rate to Candida albicans is on the rise, especially the fluconazole and ifraconazo resistance rate, 66.67% and 63.98% (Lu. X.Q. et al. 2009). The antifungus treatment is increasingly difficult. It is very essential to exploit
University First Hospital (Peking). The fluconazole-resistant strains of Candida albicans were isolated from clinical by authors and identified by Chinese Academy of Medical Sciences (Nanjing) (Liu. Z.C. et al. 2012; Ma. L.L. et al. 2006). The KZY-2 which valid monomer composition purchased from Liaoning Bio-medical Technology Co. Ltd. were dispensed to different concentration. RPMI1640 medium was purchased from Shanghai BioSun Sci & Tech Co. Ltd. and prepared according to intruction. Fluconazole (FLU) were purchased from pharmaceuticals company of Ganzhou.
